Marstacimab‑Hncq 150 mg/mL Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 150 mg/mL
Reference Brands: Hympavzi (USA)
Category: Plasma Products
Marstacimab-hncq is a human monoclonal IgG1 antibody that antagonizes the tissue factor pathway inhibitor (TFPI), thereby promoting thrombin generation and improving clot formation in patients with haemophilia A or B without inhibitors. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents (≥ 12 years) with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors.
Marstacimab‑Hncq — third party manufacturing & bulk supply
Marstacimab‑Hncq 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Marstacimab‑Hncq listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Marstacimab‑Hncq →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Marstacimab-hncq is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B who do not have inhibitors to coagulation factors VIII or IX.
Marstacimab-hncq is made from a recombinant human monoclonal antibody that targets and inhibits tissue factor pathway inhibitor (TFPI), thereby enhancing the generation of thrombin and improving blood clotting.
The trade name of Marstacimab-hncq is Amtuvemo.
Marstacimab-hncq is developed and manufactured by Pfizer Inc.
The generic name is Marstacimab-hncq.
The brand name is Amtuvemo.
Marstacimab-hncq (Amtuvemo) is manufactured by Pfizer Inc., in the United States.
Related Products
Emicizumab‑Kxwh
Strength:
30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL
Form: Injection
Reference Brands: Hemlibra (USA/EU)
View Details
Concizumab-Mtci
Strength:
60 mg/1.5 mL, 150 mg/1.5 mL, 300 mg/3 mL
Form: Prefilled autoinjector
Reference Brands: Alhemo (USA/EU)
View Details
Fresh Frozen Plasma (Ffp) Powder For Reconstitution Or Liquid
Strength:
available in 200-250 mL units
Form: liquid units or lyophilized (freeze-dried) powder
Reference Brands: No specific brands
View Details
Plasma Protein Fraction (Ppf) Powder
Strength:
50 mL, 250 mL, or 500 mL
Form: Lyophilized Powder or Liquid
Reference Brands: Plasmanate (US), Octaplas LG, Biotest Plasma (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
